Merck & Co. stock: ESMO investor event is set for October 26 for Merck & Co. stock

Published on 10/21/2026 at 15:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales reached USD 16.60 billion on August 4, 2026. Merck & Co. stock costs EUR 131.08 on October 21, 2026, down 0.70 percent versus Xetra close.

Reporting dates and sales

Merck & Co. scheduled its ESMO investor event for October 26, 2026.
Second-quarter sales reached USD 16.60 billion on August 4, 2026.
Merck & Co. stock costs EUR 131.08 at Lang & Schwarz on October 21, 2026 at 3:30 p.m. CEST, 0.70 percent below the Xetra close of October 20, 2026.
Merck & Co. is scheduled to report third-quarter results on October 29, 2026.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c — Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck & Co. has scheduled an investor event at ESMO for October 26, 2026, according to Merck & Co. The stock was trading at EUR 131.08 at Lang & Schwarz on October 21, 2026 at 3:30 p.m. CEST, down 0.70 percent versus the Xetra close of October 20, 2026 at EUR 132.00.

ESMO date comes first

The October 26 event is the next scheduled investor date shown on Merck's investor-relations calendar. The company also lists its third-quarter 2026 earnings announcement for October 29, 2026, according to Yahoo Finance.

That sequence gives investors two dated checkpoints within three days. The ESMO event is scheduled for October 26, while the earnings announcement is listed for October 29 before the market opens.

Stock stays below its yearly high

On the NYSE, Merck & Co. was last quoted at USD 147.60 on October 21, 2026 at 9:31 a.m. ET. That was 5.94 percent below its 52-week high of USD 156.92 and 79.98 percent above its 52-week low of USD 82.01.

The company had a market capitalization of USD 364.2 billion and a price-to-earnings ratio of 118.64 on the same date. The valuation is affected by the second-quarter loss, which included acquisition-related charges.

Sales provide the operating baseline

Merck reported USD 16.60 billion in second-quarter 2026 sales on August 4, 2026, according to its investor-relations page. Standardized financial data put second-quarter revenue at USD 16.607 billion and net income attributable to common shareholders at minus USD 1.335 billion for the period ended June 30, 2026.

Keytruda and Keytruda Qlex generated USD 8.40 billion in second-quarter 2026 sales, while Winrevair produced USD 588.00 million, according to Yahoo Finance. The comparison shows the scale of Merck's established oncology franchise against a newer growth product.

Comparison with peers

Merck & Co.: down 0.70 percent versus the Xetra close, P/E 118.64, market capitalization USD 364.2 billion.

Bristol-Myers Squibb Company (NYSE, USD): down 0.78 percent, P/E 13.59, market capitalization USD 125.0 billion.

Pfizer Inc. (NYSE, USD): down 0.63 percent, P/E 39.79, market capitalization USD 170.5 billion.

What comes before October 29?

The immediate calendar points to the ESMO investor event on October 26, followed by third-quarter results on October 29. For Merck & Co. stock, the scheduled dates sit alongside a USD 16.60 billion quarterly sales base and a large valuation difference versus the two pharmaceutical peers.

Merck stock in euros

At Lang & Schwarz, Merck & Co. stock was trading at EUR 131.08 on October 21, 2026 at 3:30 p.m. CEST, 0.70 percent below the Xetra close of October 20, 2026 at EUR 132.00. The next company dates are October 26 and October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.